智通财经APP获悉，和誉-B(02256)涨超11%，近一个月股价累涨超四成。截至发稿，涨11.25%，报6.43港元，成交额6371.58万港元。
消息面上，今年1月，和誉发布盈喜，预期去年总收入约为5.04亿元人民币，同比增加约4.85亿元；期内纯利不低于1000万元，同比扭亏为盈。主要归因于透过提高业务营运效率来改善成本控制；及pimicotinib(ABSK021)的对外许可协议及与默克的首付款项7000万美元。据悉，和誉将于3月3日举行董事会会议考虑及批准全年业绩。
国元国际认为，公司未来在肿瘤领域取得重磅新药，市场空间广阔，目前价值严重低估，长期看好公司的发展前景。中金研报指出，此前11月12日公司公告了匹米替尼腱鞘巨细胞瘤(TGCT)的国际关键III期临床潜在同类最佳数据，该行认为匹米替尼有竞争力的TGCT和cGvHD数据有望成为默克行使海外选择权的重要参考，建议持续关注。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.